At the recent ASCO 2024 conference, MAIA unveiled compelling interim clinical data on THIO, capturing significant attention and excitement for its potential to revolutionize cancer therapy. The latest clinical data demonstrates promising disease control, response rates, and benefits post-therapy for THIO.
Key Findings of the Ongoing Phase 2 THIO-101 Clinical Trial:
• Disease Control Rate (DCR): 85% with THIO and Libtayo in NSCLC patients who failed two or more standard-of-care therapy regimens.
• Primary Objectives: Safety and tolerability of THIO, and clinical efficacy measured by overall response rate (ORR).
THIO, combined with Libtayo, shows significant disease control in advanced NSCLC patients, indicating a promising new treatment approach for those who have exhausted other options.
The success at the ASCO 2024 conference stems from a strong collaboration between
Cromos Pharma is proud to partner with MAIA in advancing innovative cancer therapies. The company values its role in this noble endeavor and is committed to supporting MAIA's mission to improve and extend the lives of cancer patients through ongoing collaboration.
About
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Its lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
About Cromos™ Pharma
Cromos Pharma is an international CRO with expertise in delivering all aspects of clinical trials in all clinical phases and a range of therapeutic areas. Established in 2004, Cromos™ Pharma is a US-based company with strong regional presence in Central and
Contact Information:
Cromos Pharma
503 894-6091
Contact via Email
www.cromospharma.com
Read the full story here: https://www.pr.com/press-release/914337
Press Release Distributed by PR.com
Copyright © 2024 PR.com and its licensors
, source